跳至主要内容
临床试验/IRCT138711161556N7
IRCT138711161556N7已完成2 期

A double- blind placebo controlled trial of Pentoxifylline added to Risperidone in patients with autistic disorders

Tehran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
3 years 至 11 years(—)
性别
All

入选标准

  • Inclusion Criteria: DSM IV clinical diagnosis of autism, children and adolescents between the ages of 3 and 11 years (inclusive),

排除标准

  • Presence of any active medical problem, any diagnosis in Axis I and II except for mental retatdation, history of allergy to Pentoxifylline, receiving any psychotropic medications during past two weeks prior to the trial, presence of aggressive behavior that needs Risperidone

研究者

相似试验